Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Mr. Richard William Scalzo M.B.A.

Senior Vice President and Head of Finance & Administration

Mr. John G. Cox M.B.A.

Chief Executive Officer, President & Director

Dr. Romesh  Subramanian Ph.D.

Co-Founder & Advisor

Ms. Amy  Reilly

Senior Vice President and Head of Corporate Communications & Investor Relations

Mr. John  Najim M.B.A.

Chief Technical Officer

Mr. Daniel  Wilson

Senior Vice President & Head of Legal

Ms. Kate  Mitchell

Vice President & Head of Human Resources

Dr. Oxana  Beskrovnaya Ph.D.

Chief Scientific Officer

Dr. Jonathan  McNeill M.D.

Chief Business Officer

Ms. Susanna Gatti High M.B.A.

Chief Operating Officer

Biotechnologie

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. Structure de gestion

Informations sur la direction